Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance-Reference-Cited by-同舟云学术

Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance

Published:2012-01-08 Issue:2 Volume:19 Page:136-144
ISSN:1545-9993
Container-title:Nature Structural & Molecular Biology
language:en
Short-container-title:Nat Struct Mol Biol

Author:

Migliori Valentina,Müller Julius,Phalke Sameer,Low Diana,Bezzi Marco,Mok Wei Chuen,Sahu Sanjeeb Kumar,Gunaratne Jayantha,Capasso Paola,Bassi Christian,Cecatiello Valentina,De Marco Ario,Blackstock Walter,Kuznetsov Vladimir,Amati Bruno,Mapelli Marina,Guccione Ernesto

Publisher

Springer Science and Business Media LLC

Subject

Molecular Biology,Structural Biology

Link

http://www.nature.com/articles/nsmb.2209.pdf

Reference54 articles.

1. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 (2007).

2. Kirmizis, A. et al. Arginine methylation at histone H3R2 controls deposition of H3K4 trimethylation. Nature 449, 928–932 (2007).

3. Strahl, B.D. et al. Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1. Curr. Biol. 11, 996–1000 (2001).

4. Santos-Rosa, H. et al. Active genes are tri-methylated at K4 of histone H3. Nature 419, 407–411 (2002).

5. Barski, A. et al. High-resolution profiling of histone methylations in the human genome. Cell 129, 823–837 (2007).

Cited by 278 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Onametostat, a PfPRMT5 inhibitor, exhibits antimalarial activity to Plasmodium falciparum;Antimicrobial Agents and Chemotherapy;2024-08-28

2. A Chemoenzymatic Method Enables Global Enrichment and Characterization of Protein Arginine Methylation;Analytical Chemistry;2024-08-26

3. PRMT7 mediated PTEN activation promotes bone formation in female mice;2024-07-31

4. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-07-17

5. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-07-17